Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000610639
Ethics application status
Approved
Date submitted
5/10/2005
Date registered
6/10/2005
Date last updated
23/01/2017
Type of registration
Prospectively registered
Titles & IDs
Public title
A single-blinded randomised controlled trial to evaluate the pre-treatment effect of two vaginal estradiol doses compared to no treatment on the quality of pap smears in post-menopausal women.
Query!
Scientific title
A single-blinded randomised controlled trial to evaluate the pre-treatment effect of two vaginal estradiol doses compared to no treatment on the quality of pap smears in post-menopausal women.
Query!
Secondary ID [1]
528
0
New secondary ID. Please modify.
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Quality of post-menopausal pap smears
741
0
Query!
New health condition. Please modify.
2904
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
817
817
0
0
Query!
Menstruation and menopause
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Post-menopausal women presenting to two FPA Health centres for routine pap smears to be randomly assigned to a) Group 1: one tablet of estradiol to be inserted into the vagina 3 nights prior to the pap smear; b) Group 2: five tablets of estradiol to be inserted into the vagina on consecutive nights one week prior to the pap smear
Query!
Intervention code [1]
698
0
Treatment: Drugs
Query!
Comparator / control treatment
c) Control Group - no estradiol to be used prior to the pap smear.
Query!
Control group
Dose comparison
Query!
Outcomes
Primary outcome [1]
1050
0
Pap smear quality - defined as number of atrophic smears and number of smears with endocervical material absent according to established cytological criteria.
Query!
Assessment method [1]
1050
0
Query!
Timepoint [1]
1050
0
at conclusion of recruitment all smears will be reread by a "blinded" single cytologist
Query!
Secondary outcome [1]
1953
0
Subjective comfort level of pap smear procedure relative to previous smears using a Likert Scale at the conclusion of the smear.
Query!
Assessment method [1]
1953
0
Query!
Timepoint [1]
1953
0
documented at completion of smear
Query!
Eligibility
Key inclusion criteria
Naturally menopausal women with no spontaneous menses for the past 12 months; surgically menopausal women aged 20 - 70 years at least 12 months post-menopause; women in general good health who require a pap smear according to current guidelines; women who are able to consent and provide contact details.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
70
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Use of systemic or vaginal hormone replacement therapy (including Tibolone) within the past 3 months; undiagnosed vaginal bleeding; previous cone biopsy of the cervix; known hypersensitivity or allergy to consituents of vaginal tablet; inability to insert applicator; women requesting liquid-based cytology.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
A set of random numbers will be used to create a sequence contained in opaque envelopes for use by the researcher. As participants are recruited, the next envelope in the sequence is opened and the participant will be assigned to the stated group.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Subjetcs will be block randomised using a computer generated set of random numbers.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Data analysis is complete
Query!
Reason for early stopping/withdrawal
Participant recruitment difficulties
Query!
Date of first participant enrolment
Anticipated
1/11/2005
Query!
Actual
1/11/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
30/05/2008
Query!
Date of last data collection
Anticipated
Query!
Actual
1/08/2008
Query!
Sample size
Target
270
Query!
Accrual to date
Query!
Final
164
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Funding & Sponsors
Funding source category [1]
906
0
Other
Query!
Name [1]
906
0
Family Planning NSW
Query!
Address [1]
906
0
family planning NSW
328-336 Liverpool Rd
Ashfield NSW 2131
Query!
Country [1]
906
0
Australia
Query!
Funding source category [2]
3157
0
Charities/Societies/Foundations
Query!
Name [2]
3157
0
Family Planning NSW
Query!
Address [2]
3157
0
family planning NSW
328-336 Liverpool Rd
Ashfield NSW 2131
Query!
Country [2]
3157
0
Australia
Query!
Primary sponsor type
Charities/Societies/Foundations
Query!
Name
Family Planning NSW
Query!
Address
328-336 Liverpool Rd Ashfield 2131
Query!
Country
Australia
Query!
Secondary sponsor category [1]
765
0
None
Query!
Name [1]
765
0
nil
Query!
Address [1]
765
0
Query!
Country [1]
765
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
296742
0
Family Planning NSW Ethics Committee
Query!
Ethics committee address [1]
296742
0
328-336 Liverpool Rd Ashfield NSW
Query!
Ethics committee country [1]
296742
0
Australia
Query!
Date submitted for ethics approval [1]
296742
0
02/10/2003
Query!
Approval date [1]
296742
0
21/11/2003
Query!
Ethics approval number [1]
296742
0
R2003/7
Query!
Summary
Brief summary
OBJECTIVE: Atrophic Papanicolaou (Pap) smears from postmenopausal women may be unsatisfactory for assessment or result in a false-positive diagnosis of a cytological abnormality. We investigated the effect of vaginal estrogen treatment before the Pap test on the odds of an atrophic smear. METHODS: An open-label randomized controlled trial was conducted to compare the proportion of atrophic Pap smears from postmenopausal women assigned to either (1) a regimen of one 25-microg vaginal estradiol tablet inserted nightly for five nights before their Pap test, (2) a single 25-microg vaginal estradiol tablet before the test, or (3) a control group with no previous estrogen administration. All smears were reread and classified as atrophic or nonatrophic at the conclusion of the study by a single cytopathologist who was blinded to the study arms. RESULTS: One hundred fifty-four (94%) of the 164 postmenopausal women who consented to the study were included in the final analysis. Fifty-one women had received the five-night course of tablets, 50 had received one tablet, and 53 were assigned to the group with no previous estrogen use. The odds of an atrophic smear were significantly lower in women who used the five-night estrogen regimen than in women who did not use estrogen. The estimated odds ratio of an atrophic smear in the five-night regimen was 0.01 (95% CI, 0.03-0.26) compared with the no-estrogen control group. Moreover, using one tablet of estrogen had no significant effect on the likelihood of an atrophic smear compared with using none. The odds ratio of an atrophic smear in the single estrogen tablet group was 1.05 (95% CI, 0.48-2.29) compared with the no-estrogen group. CONCLUSIONS: The odds of an atrophic smear are significantly reduced for postmenopausal women who use a five-night regimen of vaginal estrogen before their Pap test.
Query!
Trial website
Query!
Trial related presentations / publications
Bateson DJ, Weisberg E. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears. Menopause 2009; 16(4): 765-9.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
35920
0
Dr Deborah Bateson
Query!
Address
35920
0
328-.336 Liverspool Road
Ashfield 2131
Query!
Country
35920
0
Australia
Query!
Phone
35920
0
+61 2 8752 4341
Query!
Fax
35920
0
Query!
Email
35920
0
[email protected]
Query!
Contact person for public queries
Name
9887
0
Dr Deborah Bateson
Query!
Address
9887
0
Sydney Centre for Reproductive Health Research
FPA Health
328 - 336 Liverpool Road
Ashfield NSW 2131
Query!
Country
9887
0
Australia
Query!
Phone
9887
0
+61 2 87524344
Query!
Fax
9887
0
Query!
Email
9887
0
[email protected]
Query!
Contact person for scientific queries
Name
815
0
Dr Deborah Bateson
Query!
Address
815
0
Sydney Centre for Reproductive Health Research
FPA Health
328 - 336 Liverpool Road
Ashfield NSW 2131
Query!
Country
815
0
Australia
Query!
Phone
815
0
+61 2 87524344
Query!
Fax
815
0
Query!
Email
815
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF